Dra. Aura A. Erazo Valle Solís. Dr. Pedro Escudero de los Ríos CMN Siglo XXI

Transcripción

1

2 6 th Anniversary Comité Científico Dra. Guadalupe Cervantes Sánchez Dra. Aura A. Erazo Valle Solís Reconocimientos por su Trayectoria Mariana Chávez Mac Gregor M.D. Anderson Dr. Pedro Escudero de los Ríos CMN Siglo XXI Dr. Carlos Sánchez Basurto MEDICAL PHARMA RESEARCH LATAM LLC ha seleccionado la Cd. de México, para la realización de eventos académicos de corte internacional, en el área de alta especialidad dónde se presentarán los últimos avances en Inmunología Oncológica, Hematologia y Sindrome Metabolico. MEDICAL PHARMA RESEARCH LATAM LLC tiene enfoque en 4 pilares fundamentales: 1. Educación Médica Contínua 2. Difusión de lo más novedoso a nivel mundial en nuestro país 3. Enfoque en Médicos Adscritos y Residentes 4. Puntos de Re Certificación Atentamente: Comité Científico de MPR LATAM LLC. Liderazgo en Educación Médica Contínua en LATAM Síguenos en redes sociales: Facebook, Instagram, Twitter y Youtube - con el hashtag #BESTOFASCOCDMX ךףך

3 Coordinadores de Módulo Jorge Alatorre Alexander - INER Germán Calderillo Ruiz - INCan Guadalupe Cervantes Sánchez - CMN 20 de Nov. Carlos Domínguez Reyes - FUCAM Mario Escobar Gómez - Hosp. Gral de México Miguel Quintana Quintana - Hosp. Naval Samuel Rivera Rivera - CMN Siglo XXI Ricardo Villalobos Valencia - CMN LA Raza Jorge Robles Aviña - PEMEX Profesores Nacionales Claudia Arce Salinas - INCan Teresa Bourlon De los Ríos - INCMNSZ Paula Cabrera Galeana - INCan Brenda Carbajal Saldaña - FUCAM Patricia Cortés Esteban - CMN 20 de Nov Georgina Garnica Jaliffe - Hosp. Gral. de México Gómez García Eva - COE ISSEMYN César González Morales - Hosp. Militar Osvaldo Hernández Flores - HRAE Bicentenario Marytere Herrera Martínez - FUCAM David Huitzil Meléndez - INCMNSZ Alejandro Juárez Ramiro - CMN 20 de Nov. Horacio López Basave - INCan Ana Martin Aguilar - CMN Siglo XXI Luis Martínez Barrera - INER Gloria Martínez Martínez - CMN Siglo XXI Héctor Martínez Nutes - Hosp. Gral. de México Rafael Medrano Guzmán - CMN Siglo XXI Pabel Miranda Aguirre - CMN 20 de Nov Carlos Monroy Álvarez - INR Josué Mora Pérez - Hosp. Naval Flavia Morales Vázquez - FUCAM David Orta Cortés - Hosp. Naval Mario Pérez Martínez - PEMEX Perla Pérez Pérez - CMN 20 de Nov. Jerónimo Rodríguez Cid - Hosp. Médica Sur Adalberto Toriz José - Hosp. Naval Laura Torrecillas Torres - CMN 20 de Nov. Ana Zempoalteca López - FUCAM

4 6 th Anniversary MIÉRCOLES 4 DE JULIO 8:00 Registro 8:45 Inauguración Presidium: Dra. Erazo Valle, Dra. Guadalupe Cervantes Sanchez, Dr. Enrique Bargallo, Dr. Carlos Dominguez, Dr. Gregorio Quintero, Dr. Pedro Escudero, Dr. Sergio Rodríguez Cuevas, Lic. David Erazo 9:00 Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial. 9:10 TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptorpositive, HER2-negative, node negative breast cancer and an intermediate prognosis 21-gene recurrence score. 9:20 PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results. Dra. Brenda Carbajal - Maestra de Ceremonias Dra. Ana Zempoalteca - FUCAM Dra. Brenda Carbajal - FUCAM Dra. Marytere Herrera - FUCAM 9:30 Mesa Redonda Dr. Carlos Domínguez - FUCAM 9:45 Tratamiento de Cáncer de Ovario y Cáncer de Cólon y Recto: entendiendo la complejidad del manejo actual. 10:35 Coffee Break 11:05 Comparison of survival between upfront primary debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomized trial: JCOG :15 Adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for uterus-limited, highgrade leiomyosarcoma: A phase III GOG study. 11:25 Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B- ENGOT OV17. Dra. Patricia Cortés - CMN 20 de Nov. Dra. Flavia Morales - FUCAM Dra. Georgina Garnica - Hosp. General de México Dra. Eva Gómez - COE Issemyn 11:35 Mesa Redonda Dra. Guadalupe Cervantes - CMN 20 de Nov. 11:50 Cáncer de Mama Metastásico RH+ Her2- Dr. José Adalberto Toriz - Hospital Naval 12:40 Coffee Break / Lunch Box ךףך

5 13:00 Final analysis of DECOG-SLT trial: No survival benefit for complete lymph node dissection in melanoma patients with positive sentinel node. 13:10 Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/ IV melanoma: Updated results from a phase III trial (CheckMate 238). Dr. Mario Pérez - PEMEX Dr. Mario Pérez - PEMEX 13:20 Mesa Redonda Dr. Jorge Robles - PEMEX 13:35 Multicenter Phase II Trial of Palbociclib, a Selective Cyclin Dependent Kinase (CDK) 4/6 Inhibitor, and Cetuximab in Platinum-Resistant HPV Unrelated (-) Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC). 13:45 A phase II randomized trial of nivolumab with stereotactic body radiotherapy (SBRT) versus nivolumab alone in metastatic (M1) head and neck squamous cell carcinoma (HNSCC). Dr. Alejandro Juárez - CMN 20 de Nov. Dr. Héctor Martínez - Hosp. Gral de México 13:55 Mesa Redonda Dr. Mario Escobar - Hosp Gral de México 14:10 Long-term results of the ADORE trial: adjuvant oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX) versus 5-fluorouracil and leucovorin (FL) after preoperative chemoradiotherapy and surgery for locally advanced rectal cancer. 14:20 A Unicancer phase III trial of hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. 14:30 Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized controlled phase III trial of adjuvant mfolfirinox versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas. 14:40 A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211). 14:50 Chemoprevention of esophageal cancer with esomeprazole and aspirin therapy: Efficacy and safety in the phase III randomized factorial ASPECT trial. Dra. Laura Torrecillas - CMN 20 de Nov. Dr. Horacio López - INCAN Dr. Rafael Medrano - CMN Siglo XXI Dr. David Huitzil - INCMNSZ Dr. Cesar González - Hosp. Militar 15:00 Mesa Redonda Dr. Germán Calderillo - INCAN

6 6 th Anniversary JUEVES 5 DE JULIO 7:30 Registro Dr. Pabel Miranda - Maestro de Ceremonias 9:00 Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2- negative (HER2 ) advanced breast cancer (ABC): Results from MONALEESA-3. 9:10 Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER. Dra. Paula Cabrera - INCAN Dra. Claudia Arce - INCAN 9:20 Mesa Redonda Dr. Ricardo Villalobos - CMN La Raza 9:35 Nuevo perfil de Eribulina para el tratamiento de cáncer de Mama Metastásico más allá de Antraciclinas y Taxanos. 10:25 Carmena: Cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinoma Results of a phase III noninferiority trial. 10:35 A randomized phase III trial between adjuvant docetaxel and surveillance after radical radiotherapy for intermediate and high risk prostate cancer: Results of SPCG-13 trial. 10:45 Keynote-199: pembrolizumab (pembro) for docetaxelrefractory metastatic castration-resistant prostate cancer (mcrpc). Dra. Mariana Chávez Mac Gregor - MD Anderson Dra. Perla Pérez - CMN 20 de Nov. Dra. Ana Martín - CMN Siglo XXI Dra. María Teresa Bourlon - INCMNSZ 10:55 Mesa Redonda Dr. Samuel Rivera - CMN Siglo XXI 11:10 Coffee Break 11:40 Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927). 11:50 Improving Communication with Older Patients with Cancer using Geriatric Assessment (GA): A University of Rochester NCI Community Oncology Research Program (NCORP) Cluster Randomized Controlled Trial (CRCT). 12:00 Randomized Trial of a Symptom Monitoring Intervention for Hospitalized Patients with Cancer. Dr. Josué Mora - Hosp. Naval Dr. David Orta - Hosp. Naval Dra. Gloria Martínez - CMN Siglo XXI 12:10 Mesa Redonda Dr. Miguel Quintana - Hosp. Naval ךףך

7 12:25 Actualidades en el manejo del dolor en el paciente oncológico 13:15 Coffee Break / Lunch Box 13:45 Keynote-407 Phase 3 Study of carboplatin-paclitaxel/ Nab-paclitaxel with or without pembrolizumab for metastatic squamous NSCLC. 13:55 Pembrolizumab versus platinum-based chemotherapy as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) 1%; open label, phase 3 KEYNOTE 042- study. 14:05 Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations. NEJ026. Dr. Carlos Monroy - INR Dr. Jeronimo Rodríguez - Hosp. Medica Sur Dr. Luis Martínez - INER Dr. Osvaldo Hernández - HRAE Bicentenario 14:15 Mesa Redonda Dr. Jorge Alatorre - INER 14:30 Reconocimiento al Dr. Pedro Escudero de los Ríos, Carlos Sánchez Basurto, Dr. Félix Quijano, Dr Ernesto Forgach y Dra. Mariana Chávez Mac Gregor 14:50 Cocktail Clausura

8